38728 Federal Register / Vol. 86, No. 138 / Thursday, July 22, 2021 / Notices 

2 Up to 30 states and/or territories will be asked to complete a follow-up survey. 

3 Up to two conditions may be reviewed per year. 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2021–15598 Filed 7–21–21; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Heritable Disorders in Newborns and 

Children 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the Public 

Health Service Act and the Federal 

Advisory Committee Act, this notice 

announces that the Advisory Committee 

on Heritable Disorders in Newborns and 

Children (ACHDNC or Committee) has 

scheduled a public meeting to be held 

on Thursday, August 12, 2021, and 

Friday, August 13, 2021. Information 

about the ACHDNC and the agenda for 

this meeting can be found on the 

ACHDNC website at https://

www.hrsa.gov/advisory-committees/ 

heritable-disorders/index.html. 

DATES: Thursday, August 12, 2021, from 

10:00 a.m. to 2:15 p.m. Eastern Time 

(ET) and Friday, August 13, 2021, from 

10:00 a.m. to 2:00 p.m. ET. 

ADDRESSES: This meeting will be held 

via webinar. While this meeting is open 

to the public, advance registration is 

required. 

Please register online at https://

www.achdncmeetings.org/registration/ 

by the deadline of 12:00 p.m. ET on 

August 11, 2021. Instructions on how to 

access the meeting via webcast will be 

provided upon registration. 

FOR FURTHER INFORMATION CONTACT: 

Alaina Harris, Maternal and Child 

Health Bureau, HRSA, 5600 Fishers 

Lane, Rockville, Maryland 20857; 301– 

443–0721; or ACHDNC@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACHDNC 

provides advice and recommendations 

to the Secretary of HHS (Secretary) on 

the development of newborn screening 

activities, technologies, policies, 

guidelines, and programs for effectively 

reducing morbidity and mortality in 

newborns and children having, or at risk 

for, heritable disorders. The ACHDNC 

reviews and reports regularly on 

newborn and childhood screening 

practices, recommends improvements in 

the national newborn and childhood 

screening programs, and fulfills 

requirements stated in the authorizing 

legislation. In addition, ACHDNC’s 

recommendations regarding inclusion of 

additional conditions for screening, 

following adoption by the Secretary, are 

evidence-informed preventive health 

services provided for in the 

comprehensive guidelines supported by 

HRSA through the Recommended 

Uniform Screening Panel pursuant to 

section 2713 of the Public Health 

Service Act (42 U.S.C. 300gg–13). Under 

this provision, non-grandfathered group 

health plans and health insurance 

issuers offering group or individual 

health insurance are required to provide 

insurance coverage without cost-sharing 

(a co-payment, co-insurance, or 

deductible) for preventive services for 

plan years (i.e., policy years) beginning 

on or after the date that is one year from 

the Secretary’s adoption of the 

condition for screening. 

During the August 12–13, 2021, 

meeting, ACHDNC will hear from 

experts in the fields of public health, 

medicine, heritable disorders, rare 

disorders, and newborn screening. 

Agenda items include the following: 

(1) Overview of the Committee’s 

review of its evidence-review processes 

and proposed updates, 

(2) A presentation on phase one of the 

mucopolysaccharidosis type II evidence 

review, 

(3) Guanidinoacetate 

methyltransferase (GAMT) deficiency 

nomination summary, 

(4) Possible Committee vote on 

whether to move GAMT deficiency 

forward to a full evidence review, 

(5) Committee discussion on emerging 

issues for newborn screening, 

(6) A panel presentation on national 

registries followed by Committee 

discussion, 

(7) A panel presentation on emerging 

issues facing the newborn screening 

workforce followed by Committee 

discussion, and 

(8) Public comments on any newborn 

screening related topic. 

The public is also encouraged to 

provide public comment on the 

proposed updates to the Committee’s 

evidence review processes. For 

reference, a summary of questions for 

public consideration is on the ACHDNC 

website. We request that public 

participants providing oral comments 

on the review of the Committee’s 

evidence review process also submit a 

written version of their remarks. 

The agenda for this meeting does not 

include any vote or decision to 

recommend a condition for inclusion in 

the Recommended Uniform Screening 

Panel. As noted in the agenda items, the 

Committee may hold a vote on whether 

or not to recommend a nominated 

condition (GAMT deficiency) to full 

evidence review, which may lead to 

such a recommendation at a future time. 

Agenda items are subject to change as 

priorities dictate. Information about the 

ACHDNC, including a roster of members 

and past meeting summaries, is 

available on the ACHDNC website listed 

above. 

As previously noted, members of the 

public will have the opportunity to 

provide comments. Public participants 

providing general oral comments may 

submit written statements in advance of 

the scheduled meeting. Oral comments 

will be honored in the order they are 

requested and may be limited as time 

allows. Requests to provide a written 

statement or make oral comments to the 

ACHDNC must be submitted via the 

registration website by 10:00 a.m. ET on 

Monday, August 9, 2021. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Alaina 

Harris at the address and phone number 

listed above at least 10 business days 

prior to the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2021–15569 Filed 7–21–21; 8:45 am] 

BILLING CODE 4165–15–P 


lotter on DSK11XQN23PROD with NOTICES1